Show simple item record

dc.contributor.authorVargha, D
dc.contributor.authorGreene, J
dc.date.accessioned2017-11-29T16:18:14Z
dc.date.issued2017-04-29
dc.description.abstractMore so than most of its European neighbours, Spain at the turn of the 21st century thought it had relegated diphtheria to the past: the country had not seen a case of diphtheria since 1986. Not, that is, until a 6-year old boy was diagnosed with the disease in May, 2015. Although diphtheria has been a curable disease since the development of diphtheria antitoxin (DAT) in the 1890s and its widespread manufacture in the early 20th century, scarcely a month after his diagnosis, the child succumbed to this disease thought to have been largely tamed by modern medical science.en_GB
dc.identifier.citationVol. 389 (10080), pp. 1690–1691en_GB
dc.identifier.doi10.1016/S0140-6736(17)31069-3
dc.identifier.urihttp://hdl.handle.net/10871/30505
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rights© 2017 Elsevier Ltd. All rights reserved.en_GB
dc.titleGrey-market medicines: Diphtheria antitoxin and the decay of biomedical infrastructureen_GB
dc.typeArticleen_GB
dc.date.available2017-11-29T16:18:14Z
dc.identifier.issn0140-6736
dc.descriptionThis is the author accepted manuscript. The final version is available from Elsevier via the DOI in this record.en_GB
dc.identifier.journalLanceten_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record